Neurocognitive functioning and psychological outcomes in advanced cancer survivors treated with immune checkpoint blockade: A prospective longitudinal study
Cancer · 01.12.2026 · 132 (23)
DOI: 10.1002/cncr.70668 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 18.11.2026. Verfasst von Nathalie Vanlaer und 6 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
Immune checkpoint blockade (ICB) has led to a growing population of long‐term advanced cancer survivors. However, data on neurocognitive functioning (NCF) and psychological outcomes after ICB remain limited, particularly from longitudinal studies incorporating control groups.
Methods
In this prospective longitudinal study, cancer survivors who had ICB‐treated, unresectable, stage III–IV disease completed neuropsychological testing and patient‐reported outcome measures (PROMs) at baseline and at 6‐month and 18‐month follow‐up.
Objective
NCF was compared with healthy matched controls. Linear mixed models evaluated longitudinal changes, and correlation analyses examined associations between NCF and PROMs.
Results
Of the 112 eligible patients, 79 were included. The median time since ICB initiation was 5.3 years. Compared with matched controls, survivors demonstrated poorer performance in learning and long‐term memory. Objective neurocognitive test performance improved over time, with the prevalence of neurocognitive impairment decreasing from 49% to 27%. Subjective cognitive complaints affected 20% of survivors, remained stable, and were strongly associated with anxiety, depressive symptoms, fatigue, post‐traumatic stress disorder, fear of cancer recurrence, and poorer quality of life, but not with objective NCF. Significant fear of cancer recurrence affected 53% of survivors, including 22% with pathologic levels, and persisted over time. Fatigue, anxiety, depressive symptoms, and post‐traumatic stress disorder symptoms were also prevalent and stable throughout follow‐up.
Conclusions
Survivors who received treatment with ICB demonstrated poorer neurocognitive test performance than healthy matched controls, particularly in learning and memory, but showed gradual improvement over time. In contrast, psychological symptoms, especially fear of cancer recurrence, persisted. These findings support routine survivorship screening, timely referral to interventions for fear of cancer recurrence, and integrative management of cognitive and psychological symptoms.
Zitieren
APA
Vanlaer, N., Dirven, I., Bertels, C., Delgado‐Alonso, C., Matias‐Guiu, J. A., Neyns, B., & Rogiers, A. (2026). Neurocognitive functioning and psychological outcomes in advanced cancer survivors treated with immune checkpoint blockade: A prospective longitudinal study. Cancer, 132(23). https://doi.org/10.1002/cncr.70668
Vancouver
Vanlaer N, Dirven I, Bertels C, Delgado‐Alonso C, Matias‐Guiu JA, Neyns B, et al. Neurocognitive functioning and psychological outcomes in advanced cancer survivors treated with immune checkpoint blockade: A prospective longitudinal study. Cancer. 2026;132(23). doi:10.1002/cncr.70668
BibTeX
@article{Vanlaer2026,
author = {Vanlaer, Nathalie and Dirven, Iris and Bertels, Cleo and Delgado‐Alonso, Cristina and Matias‐Guiu, Jordi A. and Neyns, Bart and Rogiers, Anne},
title = {Neurocognitive functioning and psychological outcomes in advanced cancer survivors treated with immune checkpoint blockade: A prospective longitudinal study},
journal = {Cancer},
year = {2026},
volume = {132},
number = {23},
doi = {10.1002/cncr.70668}
}
EUVIMED